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Abstract
Purpose: We report our experience of using helical tomotherapy (HT) to treat large and irregular shaped loco-
regional advanced breast cancer target volumes embracing various organs at risk.
Patients and methods: We retrospectively analyzed 26 patients treated for very large, irregular shaped breast
cancers. Patients were treated either with the intent to achieve local control in a primary setting (n = 14) or in a
reirradiation setting (n = 12). The recurrence group was heavily pretreated with systemic therapy. Tumors were
characterized by wide infiltration of the skin, encompassing mostly a complete hemithorax. The primary group
underwent irradiation of supraclavicular, infraclavicular, axillary and parasternal lymphonodal region. Radiotherapy
was combined with chemotherapy (n = 11). We assessed the PTV volume and its craniocaudal extension, the dose
to the organs at risk, acute toxicity and survival.
Results: Median PTV was 2276 cm3 (1476–6837 cm3) with a median cranio-caudal extension of 28 cm (15–52 cm).
The median dose to PTV was 40 Gy (32–60Gy). HT could be carried out in all patients without interruption. The
acute toxicities were mild to moderate. The median LRFS and OS after radiotherapy was 21 and 57 months for the
primary group versus 10 and 11 months for the recurrence group. Median PFS was 18 months (primary group) and
7 months (recurrence group).
Conclusions: HT is feasible for advanced thorax embracing target volumes with acceptable acute toxicity. Both
curative and palliative indications can be considered good indications based on treatment volume and anatomical
constellation.
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Introduction
The standard of care for the treatment of local breast
cancer recurrence is surgery. High local control rates
can be achieved with mastectomy after primary breast
conserving therapy [1].
In case of inoperable locally advanced chest wall recur-
rences the standard treatment is radiotherapy [2]. However
in most cases whole breast irradiation after breast conserv-
ing surgery was performed beforehand. Thus, exposure of
preirradiated normal tissue (skin, soft tissues, bones, lungs,
heart) limits the reirradiation options.
Radiotherapy for large and complexly shaped tumor
volumes in case of local recurrence or primary locally
advanced tumor is often not reasonably achievable with
conventional 3D conformal radiotherapy (3D-CRT). This
is mostly due to the fact, that the tumor partly embraces
organs at risk (OAR) such as the lungs or heart [3].
Planning studies for the use of helical tomotherapy (HT)
for breast cancer treatment have been shown to improve
conformality to the tumor bed, while sparing organs at
risk (OARs). While HT has been studied after breast
conserving surgery in the context of partial breast radi-
ation [4, 5], whole breast radiation [6] and loco regional
nodal radiation [3] only few data are available on the
feasibility, acute side effects and outcome of helical
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tomotherapy in the context of large chest wall recur-
rences and reirradiation and primary locally advanced
tumor volumes [7, 8].
The following retrospective analysis presents a single
university center experience with treatment of advanced
breast cancer with/without chemotherapy using HT.
Material and methods
Patient characteristics
From April 2007 to August 2011, 26 patients (age range:
34–79 years) were treated for very large, irregular
shaped local recurrences (n = 12) or for locally advanced
breast cancer in a primary setting (n = 14) with HT. Table
1 depicts the patients' characteristics. HT was at the
given time the only machine available in our department
that could perform IMRT and (daily) CT based IGRT
and treat extensive volumes.
Reccurence group
All patients in the recurrence group were treated with a
palliative intent. Tumors in this group were character-
ized by wide infiltration of the skin and subcutaneous
tissue as well as extensive lymph node metastases. Pallia-
tive treatment was offered for ulcerating tumors, pain
and/or neurological symptoms in patients with extensive
bulky disease. Six patients received an additional individ-
ualized boost treatment with neutrons. Neutrons are
used on a routine basis in our department in a third or
higher reirradiation setting of extended cutaneous/sub-
cutaneous metastasis. Ten patients had distant metasta-
ses and ongoing systemic therapies. Most patients were
heavily pretreated and systemic therapies varied depend-
ing on the pretreatment. For nine patients it was neces-
sary to continue dose-reduced chemotherapy during
reiradiation because of systemic progression. Nine of the
12 patients (75%) in the recurrence group had initially
received breast conserving surgery followed by whole
breast radiotherapy (WBRT). Three patients had radical
mastectomy. Figure 1 depicts a typical patient from the
recurrence group.
Primary setting group
Patients in primary setting had locally advanced tumors
with extensive involvement of axillary lymph nodes
(bulky disease) and macroscopic parasternal lymph
nodes or were at high risk of parasternal lymph nodes
metastases. One patient underwent polychemotherapy
without surgery. 8 of 14 (57%) patients underwent
Table 1 Patients’ characteristics
All patients Recurrence Treatment Group Primary Treatment Group
Descriptive characteristics
n 26 (100%) 12 (100%) 14 (100%)
Median age (range) 63 (31–75) 52 (31–75) 69 (62–74)
Median Karnofsky Performance Score (range) 90% (70–90%) 90% (70-90%) 90% (80–90%)
Distant metastases 13 (50%) 6 (50%) 7 (50%)
Histology
Invasiv ductal 21 (81%) 9 (75%) 12 (86%)
Invasiv lobular 4 (15%) 2 (17%) 2 (14%)
Angiosarcoma 1 (4%) 1 (8%) −
Side
Left side 12 (46%) 6 (50%) 6 (43%)
Right side 10 (38%) 4 (33%) 6 (43%)
Bilateral 4 (15%) 2 (17%) 2 (14%)
Symptoms at radiotherapy start
Exulcerating/painful tumour 8 (31%) 6 (50%) 2 (14%)
Extensive lymph node metastases with lymphedema 9 (35%) 5 (42%) 4 (29%)
Previous treatments
Breast conserving surgery 15 (58%) 9 (75%) 6 (43%)
Median Dose WBRT − 60 Gy (50.4–66 Gy) −
Prior radical mastectomy 14 (54%) 3 (25%) 11 (79%)
Prior polychemotherapy 10 (38%) 6 (50%) 4 (29%)
Prior adjuvant endocrine treatment 15 (57%) 4 (33%) 11 (79%)
Depicted are absolute values or median values with range
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radical mastectomy and the remaining 6 (43%) patients
received breast conserving surgery. Nonetheless in 3 of
these 6 patients radical mastectomy was necessary after
a prior breast conserving attempt. Seven of the 14 (50%)
patients had positive resection margins (5 pts.- R1 resec-
tion, 2 pts.- R2 resection) after radical mastectomy. Five
of the 11 (45%) patients after radical mastectomy had
extensive lymphangiosis carcinomatosa.
Treatment planning and delivery
Before treatment, each patient underwent a planning
computer tomography (CT) scan (Siemens Somatom;
Siemens Inc., Erlangen, Germany) with an axial slice
thickness of 3 mm. A vaccum bag (Bodyfix, Medical
Intelligence, Schwabmuenchen, Germany) was used for
immobilization. The contouring of the PTV and the
OARs was performed on the Oncentra Master-Plan sys-
tem (Nucletron B.V., Veenendaal, The Netherlands) and
iPlan (Brainlab, Feldkirchen, Germany). Treatment plan-
ning was done using Tomotherapy HI-Art System®
(Accuray Inc., Sunnyvale CA, USA). The prescribed dose
to the PTV was dependent on previous irradiation re-
gimes and ranged from 32 to 60 Gy with a median PTV
dose of 40 Gy. Organs at risk (OARs) were contoured
according to internal guidelines and constraints were set
according to Emami et al. [9]. In case of reirradiation,
the spinal cord biological equivalent dose was calculated
according to Nieder et al. [10]. All patients underwent
Fig. 1 Patient from the recurrence treatment group a: clinical appearence at the start of HT; b: clinical appearence 6 weeks after HT; c: HT
treatment plan; d DVH
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daily image guided radiotherapy (IGRT). After acquisi-
tion and reconstruction, the daily megavoltage CT scans
(MVCT) were automatically registered, by choosing the
bone and tissue algorithm provided by TomoTherapy, to
the planning CT. To account for the best positioning of
the patient, every automatic registration was controlled
and corrected by experienced staff members before
treatment.
Outcome
Acute toxicity was assessed using the Radiation Therapy
Oncology Group/National Cancer Institute Common Tox-
icity Criteria (RTOG/NCI CTC), version 3.0, morbidity
scales. Acute toxicity was assessed every week during HT
and 6–8 weeks after treatment. The planned follow up
visits were: 6–8 weeks after HT, 3, 6 and 12 months after
HT and thereafter once a year. Most clinical follow up data
presented herein on local control was collected from the
first visit 6–8 weeks after treatment. Many patients were
then lost to follow up and there is not enough data available
to reliably assess the late side effects. Treatment response
was measured by clinical examination and radiological find-
ings. Complete response was defined as the clinical dis-
appearance of all irradiated target lesions. A partial
response was defined as a decrease of more than 50% of
the target lesion. Stable disease was defined as a decrease
less than 50% or no change. Progressive disease was defined
as an increase of target lesions or appearance of new lesions
(“in field” or throughout the body). Data for PFS, LRFS and
OS was collected from different sources (patient records,
data from primary oncologists, the Munich Cancer Regis-
try). Data are reported by means of descriptive statistics
and Kaplan Meier survival function.
Results
Treatment parameters
HT could be carried out to the planned cumulative dose
in all patients without interruption.
Table 2 depicts the treatment parameters for both
treatment groups.
12 patients with extensive local recurrences received
a total reirradiation dose which ranged from 32 to
60 Gy total dose (1.8–3 Gy daily) depending on pal-
liative need, time between initial therapy and retreat-
ment and initial irradiation dose. Two patients were
treated with a simultaneous integrated boost, one pa-
tient with electron boost and six with neutron boost.
The median interval between initial radiotherapy and
reirradiation was 2.4 years (1–21 years). The median
dose from the previous radiotherapy was 60 Gy
(50.4–66 Gy). The 14 patients with primary locally
advanced tumors received a total dose between 40
and 60 Gy. Three patients were treated with a simul-
taneous integrated boost.
The median mean dose (Dmean) to the heart in the
primary and retreatment group was 13 Gy (1.5–34 Gy)
and 12Gy (6–22 Gy) and the median Dmean to the lung
was 21Gy (12–25.5 Gy) in the primary treatment group
and 16Gy (5–20 Gy) in the retreatment group, respect-
ively. Overall, the V5 was 95% (25–100%); the V20 18%
(5–45%) and the V30 12%(1–27%). Overall 11 patients
received a combined radiochemotherapy depending on
pretreatment, systemic progression and kidney function
(Table 2). Five patients received capecitabine (825 mg/
m2 bid, including weekends), Four patients vinorelbine
(25 mg/m2 8q or 60 mg/m214q), one patient doxorubi-
cin (40 mg q28d) and one patient sunitinib (12,5 mg
daily). Concurrent chemotherapy was well tolerated and
could be carried out as planned during HT treatment
without interruptions. Additionally, four patients contin-
ued endocrine treatment (two patients anastrozol, two
patients letrozol).
Acute side effects
The acute toxicity was mild to moderate measured
weekly during therapy, 6–8 weeks and three to 4 months
after treatment. Table 3 depicts the acute side effects.
Outcome
Overall, at the end of the treatment 23% (n = 6/26) pa-
tients had a local partial remission, 69% (n = 18/26) a
stable disease, 7.7% (n = 2/26) a local progressive disease
and 15% (n = 4/26) had already a systemic progression.
Six to eight weeks after HT 50% (n = 6/12) of the retreat-
ment group showed a local partial remission and 33%
(4/12) showed a complete local remission “in field”. All
four patients received a neutron boost.
Table 4 depicts the local outcome and the early side
effects. Three to four months after HT 3 patients de-
ceased and 6 patients were lost to follow up. Overall 18%
(3/17) showed local progression and 29% (5/17) had sys-
temic progression.
The median local recurrence free survival (LRFS) after
radiotherapy was 21 months for the primary treatment
group and 10 months for the recurrence group. Median
overall survival (OS) after HT was 57 months (0–120
months) for the primary treatment group and 11 months
(0.3–22 months) for the recurrence group. In the pri-
mary treatment group four patients died of systemic
progress within the observing interval. In the recurrence
group seven patients died of systemic progress within
the observing interval. Median progression free survival
(PFS) after HT was 43 months for the primary treatment
group and 7 months for the recurrence group. Figure 2
depicts the overall survival (OS), progression free sur-
vival (PFS) and local recurrence free survival (LRFS)
after HT for each group.
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Discussion
Patients with locally advanced breast cancer in the pri-
mary setting are managed in a multidisciplinary ap-
proach. Operable tumors may be managed with
modified radical mastectomy followed by chemotherapy
and locoregional radiotherapy. Inoperable tumors may
be treated with neoadjuvant chemotherapy followed by
operation and radiotherapy. Some departments perform
combined treatment with hyperthermia. Postoperative
radiotherapy (chest wall and regional lymphatics) de-
creases the risk of local recurrence after mastectomy
and improves overall survival for patients with high risk
of local recurrence [11–13]. Internal mammary and
supraclavicular irradiation for breast cancer reduces
breast-cancer mortality and improves disease-free sur-
vival and distant disease-free survival [14].
For patients whose tumors remain inoperable after
neoadjuvant chemotherapy the management is less clear.
Some studies have used radiochemotherapy or radiation
alone performed with conventional radiation techniques
as an attempt to downsize the tumor mass before sur-
gery [15–17].
It is still unclear what is the best technique for treat-
ing extensive disease in breast cancer patients. Some
plan comparison studies are available on this topic [3,
4, 18–21]. Zhang et al. evaluated the dosimetric benefit
of volumetric modulated arc therapy (VMAT) on post-
mastectomy left-sided breast cancer patients, with the
involvement of internal mammary nodes [21]. VMAT
achieves similar or superior target coverage and a better
normal tissue sparing as compared to intensity-
modulated radiotherapy (IMRT). Haciislamoglu et al.
evaluated the dose distribution and homogeneity of
Table 2 Treatment Parameters
Recurrence Treatment Group (n = 12) Primary Treatment Group (n = 14)







a) Ipsilateral chest wall 2 patients 2patients
b) More than 1/2 of the thoracic circumference
plus loco-regional lymph nodes
4 patients 9 patients
c) More than 2/3 of the thoracic circumference
plus loco-regional lymph nodes
6 patients 3 patients
d) Extranodal metastasis within the PTV 1 patient (pleura) 2 patients (bone lesions)
e) Extensive skin metastases 4 patients
PTV volume (cm3) 2984 (1457–6837) 1330 (520–6623)
Cranio-caudal PTV extension (cm) 30 (19–52) 28 (18,2–43,5)
Median total dose 40 Gy (32–60 Gy) 50 Gy (40–60 Gy)
Median dose per fraction 2 Gy (1,8–3,0 Gy) 2,0 Gy (1,5–2,24 Gy)
Simultaneous integrated boost 2 patients (50.4/56 Gy with single
doses of 1.8/2.0Gy;
55,8/60,1 Gy with single doses
of 1.8/1.94 Gy)
3 patients (45/50 Gy with single doses
of 1.8/2.0 Gy;
45/50/56 Gy with single doses
of 1.8/2.0/2.24 Gy;
46Gy/50 with single doses of 2.0/2.17 Gy)
Neutron boost 6 patients (4.6–12Gy) −
aThe PTV comprised more than a hemi-thorax in 13 and more than two thirds of the thoracic circumference in 9 patients










Radiotherapy n = 26 n = 12 n = 14
Radiodermatitis °1 14 (53%) 6 (50%) 8 (57%)
Radiodermatitis °2 6 (23%) 4 (33%) 2 (14%)
Radiodermatitis °3 6 (23%) 2 (16.7%) 4 (28%)
Dysphagia °1 10 (%) 5 (42%) 5 (36%)
Lymphedema °3 3 (11%) 4 (33%) 1 (7%)
Fatigue 12 (46%) 5 (42%) 7 (50%)
Chemotherapy n = 11 n = 9 n = 2
Leucopenia °1 6 (55%) 5 (55%) 1 (50%)
Leucopenia 2 5 (42%) 4 (44%) 1 (50%)
Anemia 1 6 (55%) 6 (67%) −
Anemia 2 3 (27%) 2 (22%) 1 (50%)
Anemia 3 1 (9%) − 1 (50%)
Hand-foot-
syndrome
2 (18%) 2 (22%) −
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four different types of IMRT (forward-planned IMRT,
inverse-planned IMRT, HT and VMAT) in comparison
with standard wedged tangential-beam 3D-CRT of the
left breast in patients who had undergone lumpectomy
[20]. All evaluated modalities provided adequate cover-
age of the whole breast. HT resulted in the lowest max-
imum doses delivered to the ipsilateral organs. Thus, if
available, HT seems to be a good alternative. Chira et
al. used neoadjuvant radiochemotherapy by helical
tomotherapy for a group of 5 patients with locally ad-
vanced breast cancer [8]. All patients underwent mast-
ectomy after radiotherapy. The preliminary results of
Chira et al. showed that HT is feasible for neoadjuvant
radiotherapy with acceptable toxicity profiles. Similarly,
our patients treated in a primary setting with internal
mammary and medial paraclavicular irradiation had
low acute toxicities despite the very large treated vol-
umes (maximum 6623 cm3). The median LRFS was
21 months and the median OS was 57 months.
Literature on reirradiation for locally advanced breast
cancer recurrences with extensive skin infiltration and
large bulky disease is sparse and not available on a sys-
tematic base concerning radiotherapy techniques or
concurrent chemotherapy treatment. Some authors
showed that reirradiation by 3D-CRT for patients with
isolated local breast cancer recurrence should be con-
sidered as a salvage treatment with low to moderate
toxicity and durable loco-regional control [7, 22–24].
Chatterjee et al. used HT for re-irradiation of three
cases of supraclavicular disease from breast cancer. HT
achieved a low dose to the brachial plexus without
symptoms of brachial plexopathy and good local con-
trol of the supraclavicular disease [25]. Würschmidt et
al. treated a heterogeneous group of 29 patients with
reirradiation of locoregional recurrences of breast can-
cer [24]. They analyzed patients with operable (R1 or
R0 resection) and non-operable recurrent breast tu-
mors with and without distant metastases. However,
most patients treated in this study had only a (exten-
sive) thoracic wall recurrence, with just some patients
with the axilla as simultaneous recurrence site. Thus
the different outcome as compared to our data might
be due to a more extensive disease treated in our co-
hort (for eg only two of our patients’ had a chest wall
reirradiation only). In our group of patients re-
irradiation was given with a median dose of 40 Gy to
Table 4 Local outcome and palliative effects
All patients Recurrence Treatment Group Primary Treatment Group
End of HT n = 26 n = 12 n = 14
Local partial remission 6 (23%) 4 (33%) 2 (14%)
Local complete remission − − −
Local stable disease 20 (76%) 6 (50%) 12 (85%)
Local progression 2 (8%) 2 (17%) 0
Systemic progression 4 (15%) 2 (17%) 2 (14%)
Acute symptom relief 7 (27%) 5 (42%) 2 (14%)
6–8 weeks after HT n = 23 n = 12 n = 11
Local partial remission 8 (35%) 6 (50%) 2 (18%)
Local complete remission 4 (18%) 4 (33%) −
Local stable disease 7 (30%) − 7 (64%)
Local progression 1 (4%) − 1 (9%)
Systemic progression 3 (13% 2 (17%) 1 (9%)
Lost to follow up 2 − 2
Deceased 1 − 1
3–4 months after HT n = 17 n = 8 n = 9
Local partial remission 2 (11%) − 2 (22%)
Local complete remission − − −
Local stable disease 7 (42%) 3 (38%) 4 (44%)
Local progression 3 (18%) 1 (13%) 2 (22%)
Systemic progression 5 (29%) 4 (50%) 1 (11%)
Lost to follow up 6 2 4
Deceased 3 2 1
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the PTV. Reirradiation was combined with concomitant
chemotherapy in nine cases. In our experience concur-
rent chemotherapy with reirradiation is feasible in
breast cancer without higher acute toxicity. We chose
mostly capecitabine as concurrent chemotherapy regi-
men because of the high clinical experience in combin-
ation with radiotherapy treatment.
There are no recommendations regarding DVH data
and normal tissue complication probabilities when
very large breast tumors are treated with IMRT,
VMAT or tomotherapy. For most of our analyzed pa-
tients, we recommended constraints based on Emami
et al. [9]. Few patients were treated after 2010 with
constraints based on QUANTEC [26]. The V20 and
V30 are within the known constraints; however the
V5 in our patients is fairly high as compared to the
up to date recommendations. These deviations from in-
ternal and external standard operation procedures (SOP)
is predominantly due to patients’ anatomy as well as com-
plexity of the target volumes, and were one of the
indications why tomotherapy was chosen to treat the pa-
tients. Generally, dose constraints as well as accepted tol-
erances are individual decisions made for every single
patient, and weighing of target coverage, applied dose and
sparing of normal tissue has to be done thoroughly.
Due to the retrospective nature of the study, no pro-
spective long-term follow-up data is available; cur-
rently, long-term observations are in process to assess
the long-term toxicites in these patients. One recent
publication assessed nine breast cancer patients with
a mean followup of 10.3 months [27]. A longer
follow-up was available in 6 patients and the authors
reported a pneumonitis in one of the 6 patients. This
patient had a V20 of 25% and V5 of 64% and a pre-
existing lung disease. Nonetheless, the lung V20 for
all patients ranged from 25 to 35% (mean 29%) and
the V5 for all patients ranged from 51 to 75% (mean 66%);
thus an exclusively dosimetric explanation could not be
offered by the authors [27]. Further studies are needed on
this topic.
Fig. 2 Overall survival (OS), progression free survival (PFS) and local recurrence free survival (LRFS) after HT for each group
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Conclusion
HT is feasible for locally advanced and recurrent thorax
embracing breast cancers with acceptable acute toxicity
and a good therapy effect. Depending on the volume size,
complexity as well as the individual patient’s anatomy, the
choice of helical IMRT has to be made and can lead to im-





Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
MND, CH, CS, BC, MD and SK participated in the study design, contributed to
the data collection, and draft the manuscript. SEC made important
contributions in revising the content. MM contributed to data collection and
analysis. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was evaluated by the ethics committee of Klinikum rechts der Isar.
Consent to publish was obtained.
Author details
1Department of Radiation Oncology, Klinikum rechts der Isar der
Technischen Universität München, Ismaninger Str. 22, 81675 München,
Germany. 2Praxis für Strahlentherapie, Hausham, Germany. 3Institute of
Innovative Radiotherapy (iRT), Helmholtz Zentrum München, München,
Germany.
Received: 19 February 2016 Accepted: 1 December 2016
References
1. Jobsen JJ, van der Palen J, Meerwaldt JH. The impact of age on local
control in women with pT1 breast cancer treated with conservative surgery
and radiation therapy. Eur J Cancer. 2001;37(15):1820–7.
2. Aberizk WJ, et al. The use of radiotherapy for treatment of isolated
locoregional recurrence of breast carcinoma after mastectomy. Cancer.
1986;58(6):1214–8.
3. Goddu SM, et al. Helical tomotherapy planning for left-sided breast cancer
patients with positive lymph nodes: comparison to conventional multiport
breast technique. Int J Radiat Oncol Biol Phys. 2009;73(4):1243–51.
4. Caudrelier JM, et al. Helical tomotherapy for locoregional irradiation
including the internal mammary chain in left-sided breast cancer:
dosimetric evaluation. Radiother Oncol. 2009;90(1):99–105.
5. Kainz K, et al. Investigation of helical tomotherapy for partial-breast irradiation
of prone-positioned patients. Int J Radiat Oncol Biol Phys. 2009;74(1):275–82.
6. Gonzalez VJ, et al. Evaluation of two tomotherapy-based techniques for the
delivery of whole-breast intensity-modulated radiation therapy. Int J Radiat
Oncol Biol Phys. 2006;65(1):284–90.
7. Harkenrider MM, Wilson MR, Dragun AE. Reirradiation as a component of
the multidisciplinary management of locally recurrent breast cancer. Clin
Breast Cancer. 2011;11(3):171–6.
8. Chira C, et al. Helical tomotherapy for inoperable breast cancer: a new
promising tool. Biomed Res Int. 2013;2013:264306.
9. Emami B, et al. Tolerance of normal tissue to therapeutic irradiation. Int J
Radiat Oncol Biol Phys. 1991;21(1):109–22.
10. Nieder C, et al. Update of human spinal cord reirradiation tolerance based on
additional data from 38 patients. Int J Radiat Oncol Biol Phys. 2006;66(5):1446–9.
11. Sautter-Bihl ML, et al. DEGRO practical guidelines: radiotherapy of breast
cancer III–radiotherapy of the lymphatic pathways. Strahlenther Onkol.
2014;190(4):342–51.
12. Wenz F, et al. DEGRO practical guidelines for radiotherapy of breast cancer
IV: radiotherapy following mastectomy for invasive breast cancer.
Strahlenther Onkol. 2014;190(8):705–14.
13. Ebctcg, et al. Effect of radiotherapy after mastectomy and axillary surgery on
10-year recurrence and 20-year breast cancer mortality: meta-analysis of
individual patient data for 8135 women in 22 randomised trials. Lancet.
2014;383(9935):2127–35.
14. Poortmans PM, et al. Internal mammary and medial supraclavicular
irradiation in breast cancer. N Engl J Med. 2015;373(4):317–27.
15. Bates T, et al. Primary chemo-radiotherapy in the treatment of locally
advanced and inflammatory breast cancer. Breast. 2012;21(3):330–5.
16. Matuschek C, et al. Long-term outcome after neoadjuvant
radiochemotherapy in locally advanced noninflammatory breast cancer and
predictive factors for a pathologic complete remission : results of a
multivariate analysis. Strahlenther Onkol. 2012;188(9):777–81.
17. Lerouge D, et al. Combined chemotherapy and preoperative irradiation for
locally advanced noninflammatory breast cancer: updated results in a series
of 120 patients. Int J Radiat Oncol Biol Phys. 2004;59(4):1062–73.
18. Ashenafi M, et al. Feasibility of postmastectomy treatment with helical
TomoTherapy. Int J Radiat Oncol Biol Phys. 2010;77(3):836–42.
19. Cendales R, et al. Helical tomotherapy in patients with breast cancer and
complex treatment volumes. Clin Transl Oncol. 2011;13(4):268–74.
20. Haciislamoglu E, et al. Dosimetric comparison of left-sided whole-breast
irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical
tomotherapy, and volumetric arc therapy. Phys Med. 2015;31(4):360–7.
21. Zhang Q, et al. Dosimetric comparison for volumetric modulated arc
therapy and intensity-modulated radiotherapy on the left-sided chest wall
and internal mammary nodes irradiation in treating post-mastectomy breast
cancer. Radiol Oncol. 2015;49(1):91–8.
22. Harms W, et al. Results of chest wall reirradiation using pulsed-dose-rate
(PDR) brachytherapy molds for breast cancer local recurrences. Int J Radiat
Oncol Biol Phys. 2001;49(1):205–10.
23. Deutsch M. Repeat high-dose external beam irradiation for in-breast tumor
recurrence after previous lumpectomy and whole breast irradiation. Int J
Radiat Oncol Biol Phys. 2002;53(3):687–91.
24. Wurschmidt F, et al. Reirradiation of recurrent breast cancer with and
without concurrent chemotherapy. Radiat Oncol. 2008;3:28.
25. Chatterjee S, et al. Managing supraclavicular disease from breast cancer
with brachial plexus-sparing techniques using helical tomotherapy. Clin
Oncol (R Coll Radiol). 2011;23(2):101–7.
26. Bentzen SM, et al. Quantitative Analyses of Normal Tissue Effects in the
Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol
Biol Phys. 2010;76(3 Suppl):S3–9.
27. Kaidar-Person O, et al. Helical tomotherapy for bilateral breast cancer:
Clinical experience. Breast. 2016;28:p79–83.
Duma et al. Radiation Oncology  (2017) 12:31 Page 8 of 8
